

Antonio PÃ¡ez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8021996/publications.pdf>

Version: 2024-02-01

15
papers

590
citations

1040056

9
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

756
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychological, neuropsychiatric, and quality of life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study. <i>Alzheimer's and Dementia</i> , 2022, 18, 1314-1324.	0.8	17
2	Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study. <i>Neurological Sciences</i> , 2022, 43, 3211-3221.	1.9	1
3	Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases. <i>International Immunopharmacology</i> , 2022, 104, 108472.	3.8	2
4	Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103164.	1.0	12
5	Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 843-849.	2.8	6
6	A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. <i>Alzheimer's and Dementia</i> , 2020, 16, 1412-1425.	0.8	82
7	Albumin glycation in Alzheimer's disease patients: Results from the AMBAR trial. <i>Alzheimer's and Dementia</i> , 2020, 16, e042836.	0.8	1
8	Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12115.	3.7	6
9	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
10	Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 61-69.	3.7	63
11	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid- β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 129-143.	2.6	67
12	Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 321-332.	2.6	21
13	P1048: Changes in Cognitive Status of Alzheimer's Disease Patients Treated with Plasma Exchange and Replacement with Human Albumin Plus Immunoglobulin: Interim Global Results of the Ambar Trial. <i>Alzheimer's and Dementia</i> , 2016, 12, P419.	0.8	1
14	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- β Peptide Aggregation. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 643-657.	2.6	41
15	Amyloid-targeted therapeutics in Alzheimer's disease: Use of human albumin in plasma exchange as a novel approach for abeta mobilization. <i>Drug News and Perspectives</i> , 2009, 22, 325.	1.5	92